vTv Therapeutics (VTVT) Enterprise Value (2014 - 2026)
vTv Therapeutics (VTVT) reported Enterprise Value of -$98.1 million for Q1 2026, down 225.62% on a YoY basis from $78.1 million in Q1 2025, and down 10.29% sequentially from -$88.9 million in Q4 2025.
vTv Therapeutics (VTVT) Enterprise Value (2014 - 2026) Analysis & Trends
vTv Therapeutics (VTVT) has 13 years of Enterprise Value data on file, last reported at -$98.1 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 225.62% year-over-year to -$98.1 million; the trailing twelve-month figure through Mar 2026 stood at -$98.1 million (down 225.62% YoY), and the FY2025 full-year result was -$88.9 million, down 156.07% from the prior year.
- Enterprise Value fell to -$98.1 million in Q1 2026, from -$88.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of $8.9 million in Q3 2022 to a low of -$98.5 million in Q3 2025.
- A 5-year average of -$29.0 million and a median of -$26.3 million in 2025 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value jumped 402.8% in 2023 and slumped 6770.7% in 2024, its largest moves.
- Tracing VTVT's Enterprise Value over 5 years: stood at $4.4 million in 2022, then sank by 176.16% to -$3.4 million in 2023, then tumbled by 927.49% to -$34.7 million in 2024, then sank by 156.07% to -$88.9 million in 2025, then decreased by 10.29% to -$98.1 million in 2026.
- Business Quant data shows VTVT's Enterprise Value at -$98.1 million in Q1 2026, -$88.9 million in Q4 2025, and -$98.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,913.26 Bn | 1,913.20 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.02 Bn | 466.23 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.17 Bn | 114.92 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.10 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.60 Bn | 50.42 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.39 Bn | 34.38 Bn | 959.66 Mn | -3.01 Bn |
| 10 | vTv Therapeutics | 19.17 Mn | 19.17 Mn | - | -98.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -98.09 Mn |
| Dec 31, 2025 | -88.93 Mn |
| Sep 30, 2025 | -98.50 Mn |
| Jun 30, 2025 | -26.26 Mn |
| Mar 31, 2025 | -30.12 Mn |
| Dec 31, 2024 | -34.73 Mn |
| Sep 30, 2024 | -41.69 Mn |
| Jun 30, 2024 | -41.63 Mn |
| Mar 31, 2024 | -52.37 Mn |
| Dec 31, 2023 | -3.38 Mn |
| Sep 30, 2023 | 2.51 Mn |
| Jun 30, 2023 | 6.27 Mn |
| Mar 31, 2023 | 785,000.00 |
| Dec 31, 2022 | 4.44 Mn |
| Sep 30, 2022 | 8.89 Mn |
| Jun 30, 2022 | -2.07 Mn |
| Mar 31, 2022 | 2.20 Mn |
| Dec 31, 2021 | 11.45 Mn |
| Sep 30, 2021 | 24.91 Mn |
| Jun 30, 2021 | 49.23 Mn |